Google
FULC — FULCRUM THERAPEUTICS INC (Healthcare >> Biotechnology)
FULC FAQ
What is FULC's ROE?
FULCRUM THERAPEUTICS INC reports a Return on Equity (ROE) of -22.84%.
What is FULC's dividend yield?
FULCRUM THERAPEUTICS INC offers a dividend yield of 0.00%.
What is FULC's Deepscope Quality Score?
Deepscope rates FULC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FULC?
Deepscope's AI Timing Score for FULC is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FULC belong to?
FULCRUM THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.22
Price
0.15
(4.66%)
Day Change
|
|
|---|
FULC, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.22 |
| PBV / Sector |
0.63 / 4.48
GREAT
|
| Earning Per Share | -1.17 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
10.07 M
GREAT
|
| Average 1W Daily Value |
30.99 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:11 |
| Symbol | FULC |
| Name | FULCRUM THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 66.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 209.23 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139
Phone: 617 651 8851
Website: https://www.fulcrumtx.com
Employees: 55
Sector: Healthcare >> Biotechnology
Description: Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
